{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:54:47Z","timestamp":1785495287960,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:00:00Z","timestamp":1793318400000},"content-version":"am","delay-in-days":698,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020084","name":"Guangzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515011038"],"award-info":[{"award-number":["2023A1515011038"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515011246"],"award-info":[{"award-number":["2021A1515011246"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bioorg.2024.107905","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T11:47:49Z","timestamp":1729684069000},"page":"107905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of novel Macrocyclic small molecules Based on 2-Amino-4-thiazolylpyridineas selective EGFR inhibitors with high Blood-Brain barrier penetration for the treatment of glioblastoma"],"prefix":"10.1016","volume":"153","author":[{"given":"Guowu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqiu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanhe","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107905_b0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.1241328","article-title":"Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant egfr dna","volume":"343","author":"Nathanson","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2024.107905_b0010","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11060-020-03451-6","article-title":"Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis","volume":"147","author":"Marenco-Hillembrand","year":"2020","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.bioorg.2024.107905_b0015","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.bioorg.2024.107905_b0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11910-015-0611-8","article-title":"Nitrosoureas in the management of malignant gliomas","volume":"16","author":"Brandes","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.bioorg.2024.107905_b0025","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA. Cancer. J. Clin."},{"key":"10.1016\/j.bioorg.2024.107905_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188996","article-title":"Improving the efficacy of anti-egfr drugs in gbm: where we are going?","volume":"1878","author":"Ge","year":"2023","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"10.1016\/j.bioorg.2024.107905_b0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis."},{"key":"10.1016\/j.bioorg.2024.107905_b0040","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-18-3034","article-title":"Comparison of biomarker assays for egfr: implications for precision medicine in patients with glioblastoma","volume":"25","author":"Lassman","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107905_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311110","article-title":"An overview of egfr mechanisms and their implications in targeted therapies for glioblastoma","volume":"24","author":"Rodriguez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107905_b0050","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2024.107905_b0055","first-page":"1383","article-title":"Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas","volume":"60","author":"Frederick","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107905_b0060","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"Cosmic: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.bioorg.2024.107905_b0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2213-2600(21)00166-1","article-title":"Bevacizumab plus erlotinib versus erlotinib alone in japanese patients with advanced, metastatic, egfr-mutant non-small-cell lung cancer (nej026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Kawashima","year":"2022","journal-title":"Lancet Resp. Med."},{"key":"10.1016\/j.bioorg.2024.107905_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188645","article-title":"Challenge and countermeasures for egfr targeted therapy in non-small cell lung cancer","volume":"1877","author":"Tian","year":"2022","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"10.1016\/j.bioorg.2024.107905_b0075","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and egfrviii in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2024.107905_b0080","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/neuonc\/now113","article-title":"Egfrviii mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through src activation","volume":"18","author":"Eskilsson","year":"2016","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bioorg.2024.107905_b0085","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/neuonc\/nov319","article-title":"Epidermal growth factor receptor targeting and challenges in glioblastoma","volume":"18","author":"Thorne","year":"2016","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bioorg.2024.107905_b0090","first-page":"1385","article-title":"Erlotinib osi\/roche\/genentech","volume":"3","author":"Kim","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.bioorg.2024.107905_b0095","doi-asserted-by":"crossref","unstructured":"C.R. Culy, D. Faulds, Gefitinib, Drugs 62 (2002) 2237, 2249. 10.2165\/00003495-200262150-00008.","DOI":"10.2165\/00003495-200262150-00008"},{"key":"10.1016\/j.bioorg.2024.107905_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188967","article-title":"20 years since the approval of first egfr-tki, gefitinib: insight and foresight","volume":"1878","author":"Singh","year":"2023","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"10.1016\/j.bioorg.2024.107905_b0105","doi-asserted-by":"crossref","first-page":"4441s","DOI":"10.1158\/1078-0432.CCR-06-0286","article-title":"Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer","volume":"12","author":"Heymach","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107905_b0110","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1634\/theoncologist.2015-0301","article-title":"Safety of an oral fixed combination of netupitant and palonosetron (nepa): pooled data from the phase ii\/iii clinical program","volume":"21","author":"Aapro","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2024.107905_b0115","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","article-title":"The cosmic (catalogue of somatic mutations in cancer) database and website","volume":"91","author":"Bamford","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2024.107905_b0120","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.ijrobp.2012.10.008","article-title":"Rtog 0211: a phase 1\/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients","volume":"85","author":"Chakravarti","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bioorg.2024.107905_b0125","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/1535-7163.MCT-11-0048","article-title":"Pathway analysis of glioblastoma tissue after preoperative treatment with the egfr tyrosine kinase inhibitor gefitinib\u2013a phase ii trial","volume":"10","author":"Hegi","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2024.107905_b0130","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (bibw 2992), an irreversible erbb family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2024.107905_b0135","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/acs.jmedchem.1c00217","article-title":"Synthetic opportunities and challenges for macrocyclic kinase inhibitors","volume":"64","author":"Amrhein","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107905_b0140","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nrd2590","article-title":"The exploration of macrocycles for drug discovery\u2013an underexploited structural class","volume":"7","author":"Driggers","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2024.107905_b0145","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4155\/fmc.12.93","article-title":"Macrocycles in new drug discovery","volume":"4","author":"Mallinson","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107905_b0150","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s12325-019-01198-9","article-title":"The effect of rifampin on the pharmacokinetics and safety of lorlatinib: results of a phase one, open-label, crossover study in healthy participants","volume":"37","author":"Chen","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bioorg.2024.107905_b0155","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with alk-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2024.107905_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111966","article-title":"Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent egfr inhibitors to overcome tki-resistance","volume":"187","author":"Yang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107905_b0180","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.1021\/acs.jmedchem.4c00128","article-title":"Discovery of novel small-molecule-based potential pd-l1\/egfr dual inhibitors with high druggability for glioblastoma immunotherapy","volume":"67","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107905_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105463","article-title":"Computational studies of potent covalent inhibitors on wild type or t790m\/l858r mutant epidermal growth factor receptor","volume":"152","author":"Yang","year":"2020","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824008101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824008101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:23:20Z","timestamp":1762223000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824008101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"alternative-id":["S0045206824008101"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107905","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel Macrocyclic small molecules Based on 2-Amino-4-thiazolylpyridineas selective EGFR inhibitors with high Blood-Brain barrier penetration for the treatment of glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107905"}}